NCT01091792View on ClinicalTrials.gov

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 2, 2015

Study Completion Date

April 2, 2015

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Bevacizumab

Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy

Trial Locations (1)

03756

Dartmouth Hithcock Medcial Center, Lebanon

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT01091792 - Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter